NYSEAMERICAN:NSRX Nasus Pharma (NSRX) Stock Price, News & Analysis $3.51 -0.12 (-3.31%) Closing price 10/9/2026 04:10 PM EasternExtended Trading$3.47 -0.04 (-1.08%) As of 10/9/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsSEC Filings About Nasus Pharma Stock (NYSEAMERICAN:NSRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nasus Pharma alerts:Sign Up Key Stats Today's Range$3.44▼$3.6650-Day Range$3.19▼$4.1052-Week Range$1.98▼$9.50Volume15,820 shsAverage Volume22,563 shsMarket Capitalization$41.10 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingBuy Company Overview Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company developing intranasal powder-delivery products for acute care and emergency medical conditions. Its proprietary platform is designed to deliver drug formulations through the nose in a convenient, needle-free format, with the potential to support rapid administration when patients may be unable to swallow or when immediate treatment is needed. The company’s development activities focus on applying its technology to treatments for conditions that require fast, simple dosing, including emergency and hospital-based applications. Nasus Pharma’s products remain in development, and the company’s pipeline and commercial opportunities are subject to clinical, regulatory, and other development milestones. Nasus Pharma is based in Israel and is developing its products for potential use in international pharmaceutical and healthcare markets. Publicly available information about its leadership, commercial operations, and approved products is limited.AI Generated. May Contain Errors. Read More Nasus Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreNSRX MarketRank™: Nasus Pharma scored higher than 67% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNasus Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialNasus Pharma has a consensus price target of $18.00, representing about 412.8% upside from its current price of $3.51.Amount of Analyst CoverageNasus Pharma has received no research coverage in the past 90 days.Read more about Nasus Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nasus Pharma are expected to grow in the coming year, from ($0.84) to ($0.81) per share.Price to Book Value per Share RatioNasus Pharma has a P/B Ratio of 11.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.67% of the float of Nasus Pharma has been sold short.Short Interest Ratio / Days to CoverNasus Pharma has a short interest ratio ("days to cover") of 2.87, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nasus Pharma has recently decreased by 2.85%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNasus Pharma does not currently pay a dividend.Dividend GrowthNasus Pharma does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.68 News SentimentNasus Pharma has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Nasus Pharma this week, compared to 1 article on an average week.MarketBeat Follows4 people have added Nasus Pharma to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nasus Pharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsNasus Pharma has minimal institutional ownership at this time.Read more about Nasus Pharma's insider trading history. Receive NSRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nasus Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NSRX Stock News HeadlinesNasus Pharma (NYSEAMERICAN:NSRX) Stock Price Down 4% - Here's What HappenedOctober 9 at 2:21 AM | americanbankingnews.comNasus Pharma Shareholders Approve Most Proposals at October Annual and Special MeetingOctober 8 at 5:10 PM | tipranks.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 10 at 1:00 AM | Porter & Company (Ad)Nasus Pharma, Ltd.: Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of OndansetronSeptember 30, 2026 | finanznachrichten.deNasus Pharma (NSRX) Stock Forecast & Price TargetSeptember 30, 2026 | investing.comNasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of OndansetronSeptember 29, 2026 | globenewswire.comNasus Pharma Sets Up $8.5 Million At-the-Market Equity Program to Fund Clinical PipelineSeptember 18, 2026 | tipranks.comNasus Pharma's IND Application For NS002 Gets FDA ClearanceSeptember 14, 2026 | rttnews.comSee More Headlines NSRX Stock Analysis - Frequently Asked Questions How have NSRX shares performed this year? Nasus Pharma's stock was trading at $7.10 on January 1st, 2026. Since then, NSRX shares have decreased by 50.6% and is now trading at $3.51. How were Nasus Pharma's earnings last quarter? Nasus Pharma Ltd. (NYSEAMERICAN:NSRX) issued its quarterly earnings data on Monday, August, 17th. The company reported ($0.27) earnings per share (EPS) for the quarter. How do I buy shares of Nasus Pharma? Shares of NSRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/17/2026Today10/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NSRX's financial health is in the Green zone, according to TradeSmith. NSRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:NSRX CIK2029039 Webwww.nasuspharma.com Phone972-3573-6632FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Nasus Pharma$18.00 High Price Target$18.00 Low Price Target$18.00 Potential Upside/Downside+412.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio8.77 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book11.32Miscellaneous Outstanding Shares11,710,000Free FloatN/AMarket Cap$41.10 million OptionableN/A Beta4.18 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSEAMERICAN:NSRX) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nasus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nasus Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
